NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc. (NBY)

Delisted
15 Jul 2026
AMEX AMEX
$
1. 28
+0.06
+4.918%
$
39.14M Market Cap
- P/E Ratio
1% Div Yield
127,793 Volume
- Eps
$ 1.22
Previous Close
Investors:
Day Range
1.2 1.32
Year Range
1 99.75
Want to track NBY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

NBY Chart

NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript

NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Good day, and welcome to the NovaBay Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.

Seekingalpha | 2 years ago
Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?

Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?

NovaBay Pharmaceuticals (NYSEMKT: NBY ) stock is falling hard on Thursday after the eyecare and wound care company announced results from its annual shareholder meeting. Included among the proposals in the annual shareholder meeting was a reverse stock split.

Investorplace | 2 years ago

NovaBay Pharmaceuticals, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Courtney Holt
Courtney Holt Compound Planning, Inc.
3,364.2 $94,870.44 $18,974 -$75,896.44 -80%

NovaBay Pharmaceuticals, Inc. (NBY) FAQ

What does "Delisted" mean?

NovaBay Pharmaceuticals, Inc. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

The last recorded stock split occurred on Feb 23, 2026 with a ratio of 1:5.

What was the last known trading price?

The stock last traded at $1.28 on Jul 15, 2026 before being delisted.

NovaBay Pharmaceuticals, Inc. Profile

Biotechnology Industry
Healthcare Sector
Michael Kazley CEO
AMEX Exchange
66987P508 CUSIP
US Country
13 Employees
30 Sep 2025 Last Dividend
23 Feb 2026 Last Split
- IPO Date

Overview

NovaBay Pharmaceuticals, Inc. is a healthcare company engaged in the development and commercialization of eyecare and wound care products across the United States and internationally. Known for its innovative approach towards effective healthcare solutions, the company provides a range of products targeted at improving ocular health and managing wounds. Initially named NovaCal Pharmaceuticals, Inc., it underwent a name change to NovaBay Pharmaceuticals, Inc. in February 2007. Since its incorporation in 2000, the company has been dedicated to offering products that meet the needs of patients, leveraging advanced technology and research to create effective solutions. Headquartered in Emeryville, California, NovaBay Pharmaceuticals continues to expand its portfolio and market presence, reaching a broader audience through both its web stores and various third-party online retailers and distribution partners.

Products and Services

  • Avenova Spray - A specialized solution designed for the removal of foreign materials, including microorganisms and debris from the skin around the eye, particularly the eyelid. This product aims to maintain optimal ocular hygiene and health.
  • Avenova Eye Health Support - Antioxidant-rich oral supplements developed to support overall eye health. These supplements are formulated to provide nutritional support to the eyes.
  • Avenova Lubricating Eye Drops - Engineered for instant relief, these eye drops are designed to moisturize and soothe dry eyes, providing users with immediate comfort.
  • NovaWipes by Avenova - Soft, absorbent wipes intended for the gentle cleansing of the eyelids and lashes, complementing the routine use of Avenova Spray to ensure a more comprehensive ocular hygiene regimen.
  • Avenova WarmEye Compress - A soothing solution for eyes, this compress is designed to provide warmth, helping to relieve discomfort from conditions such as dry eyes or meibomian gland dysfunction.
  • i-Chek by Avenova - An innovative tool for monitoring physical eyelid health, offering users a means to regularly check their eyelid condition and detect potential issues early on.
  • Wound Care Products - Under the brands NeutroPhase and PhaseOne, NovaBay Pharmaceuticals provides products for wound care, including solutions for cleansing and irrigation as part of surgical procedures, and for treating wounds, burns, ulcers, and other injuries. These products are crafted to aid in the healing process, ensuring effective wound management.

Contact Information

Address: 2000 Powell Street
Phone: 510 899 8800